T. Rowe Price Investment Management, Inc. Denali Therapeutics Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,638,567 shares of DNLI stock, worth $98.3 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
5,638,567
Previous 3,246,934
73.66%
Holding current value
$98.3 Million
Previous $45.4 Million
80.24%
% of portfolio
0.05%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding DNLI
# of Institutions
259Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL5.47MShares$95.3 Million0.02% of portfolio
-
State Street Corp Boston, MA5.46MShares$95.3 Million0.0% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...